Skip to main content
Vaxil Bio Ltd. logo

Vaxil Bio Ltd. — Investor Relations & Filings

Ticker · VXL ISIN · CA92243L1076 TSXV Professional, scientific and technical activities
Filings indexed 246 across all filing types
Latest filing 2026-05-01 Regulatory Filings
Country CA Canada
Listing TSXV VXL

About Vaxil Bio Ltd.

http://vaxil-bio.com

Vaxil Bio Ltd. is a biotechnology company focused on developing novel immunotherapies and targeted therapies. The company utilizes a proprietary drug discovery and development platform centered on Signal Peptides (SPs). This platform leverages signal peptide domains found on specific proteins to create targeted treatments. Vaxil's pipeline includes neoantigen-like peptide products and antibodies designed to address significant unmet medical needs in both cancer (immuno-oncology) and infectious diseases.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings
2026-05-01 English
Audited annual financial statements – English.pdf
Regulatory Filings
2026-05-01 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2025-12-17 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release covering two primary events: the completion of a private placement financing (capital raising) and changes to the Board of Directors (resignations and a new appointment). While it contains management information, the primary financial event is the closing of a private placement, which falls under 'Capital/Financing Update' (CAP). Given the dual nature, CAP is the most specific category for the financing activity described.
2025-12-04 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2025-11-27 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a non-brokered private placement of units (shares and warrants) to raise capital. It details the offering price, the use of proceeds, and the conditions for closing. This falls directly under the definition of a capital/financing update.
2025-11-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.